双等位基因1p32缺失定义超高危多发性骨髓瘤,但单等位基因del(1p32)仍是强预后因素
研究在2551例新诊断多发性骨髓瘤患者中确认1p32缺失的不良预后影响,11%携带del(1p32),总生存显著劣于无del(1p32)者(中位49个月 vs 124个月),双等位基因缺失预后更差(中位25个月 vs 60个月),多因素分析显示del(1p32)为负性预后因素。
要点
- 2551例新诊断骨髓瘤中11%携带del(1p32),中位总生存49个月 vs 无del(1p32)者124个月。
- 双等位基因del(1p32)中位总生存25个月,显著差于单等位基因者的60个月。
- del(1p32)合并其他高危细胞遗传学异常时总生存显著降低。
核心结论
- 研究确认del(1p32)在新诊断多发性骨髓瘤中具有不良预后影响,并支持在诊断时进行评估。
研究设计与样本
- 研究纳入2551例新诊断多发性骨髓瘤患者,分析del(1p32)及其他细胞遗传学异常的预后影响。
主要发现
- 2551例患者中11%携带del(1p32),其总生存显著劣于无del(1p32)者(中位49个月 vs 124个月)。
- del(1p32)患者无进展生存亦显著缩短。
- 双等位基因del(1p32)预后显著差于单等位基因del(1p32)(中位总生存25个月 vs 60个月)。
- del(1p32)合并其他高危细胞遗传学异常[del(17p)、t(4;14)或gain(1q)]时总生存显著降低。
- 多因素分析中del(1p32)为负性预后因素;调整年龄和治疗后,携带del(1p32)者疾病进展风险为1.3倍,死亡风险为1.9倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs, with which del(1p32) appears to be the second worst abnormality after del(17p). This study aimed to confirm the adverse effect of 1p32 deletion in patients with newly diagnosed multiple myeloma (NDMM). Among 2551 patients with newly diagnosed multiple myeloma, 11% were harboring del(1p32). Their overall survival (OS) was significantly inferior compared with patients without del(1p32) (median OS: 49 months vs 124 months). Likewise, progression-free survival was significantly shorter. More importantly, biallelic del(1p32) conferred a dramatically poorer prognosis than a monoallelic del(1p32) (median OS: 25 months vs 60 months). As expected, the OS of patients with del(1p32) significantly decreased when this abnormality was associated with other high-risk CAs [del(17p), t(4;14), or gain(1q)]. In the multivariate analysis, del(1p32) appeared as a negative prognostic factor; after adjustment for age and treatment, the risk of progression was 1.3 times higher among patients harboring del(1p32), and the risk of death was 1.9 times higher. At the dawn of risk-adapted treatment strategies, we have confirmed the adverse effect of del(1p32) in multiple myeloma and the relevance of its assessment at diagnosis.
引用
- Schavgoulidze A, Talbot A, Perrot A, et al. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood. 2023. PMID: 36375118. doi:10.1182/blood.2022017863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。